Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme commits $100m upfront for Voyager's gene therapy expertise in CNS

This article was originally published in Scrip

Executive Summary

Sanofi company Genzyme has entered a collaboration with Cambridge, Massachusetts-based Voyager Therapeutics focused on the discovery of gene therapies for severe CNS disorders.

You may also be interested in...



Voyager Nabs Neurocrine As Partner In CNS Gene Therapy

Voyager signals Phase II study of gene therapy VY-AADC in Parkinson's disease is on track, with no expectations for regulatory setbacks.

AbbVie's Alzheimer's Efforts Voyage Into AAV-Targeted Tau Antibodies

Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.

Voyager Cheers End Of Sanofi Partnership In Parkinson's; Investors Less Confident

The gene therapy developer described Sanofi's decision to give up ex-US rights to VY-AADC01 as good news, but its stock price fell anyway. Voyager maintains that it wasn't necessarily counting on its partner to opt in, so it has enough funding without Sanofi to conduct a Phase II/III study.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC027792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel